A University of Barcelona research team has identified a potential two-drug combination that could reverse the buildup of fat in the liver while simultaneously reducing cardiovascular death risk. The finding centers on pemafibrate and telmisartan, medications already approved for other conditions, and suggests a faster path forward than experimental therapies that have repeatedly failed in clinical trials.
Metabolic dysfunction-associated steatotic liver disease now ranks as the world's most common liver condition, affecting roughly one in three adults. The disease develops when excess fat accumulates inside liver cells, causing progressive liver damage and significantly raising the likelihood of fatal heart and blood vessel disease. Despite its prevalence, treatment options remain limited.
Researchers tested the drug combination in animal models and found that together they substantially reduced liver fat. Critically, half doses of each drug administered together proved as effective as full doses of either drug alone, suggesting the approach could minimize side effects while maximizing benefit. The treatment also appeared to lower blood pressure and cholesterol levels, further reducing cardiovascular risk.
The strategy of repurposing existing medications makes practical sense. Many experimental drugs for this liver disease have stumbled during clinical trials due to safety concerns. By contrast, pemafibrate and telmisartan have established safety records in humans, a prerequisite for treating early-stage disease that typically produces no symptoms.
Pemafibrate works as a lipid-lowering agent, while telmisartan manages blood pressure. Both target cardiovascular risk factors that commonly occur together in patients with fatty liver disease. Pemafibrate is currently available only in Japan, whereas telmisartan enjoys worldwide prescription use.
Scientists led by Marta Alegret tested the combination in both rats and zebrafish larvae. Zebrafish have emerged as valuable models for liver research because their metabolism and hepatic function closely mirror human physiology, while experiments proceed faster and cost far less than traditional approaches. In both species, the drug pairing reversed liver fat caused by a diet heavy in fat and fructose.
The study also uncovered a novel mechanism. Telmisartan restored levels of the PCK1 protein in the liver, a protein that had been depleted in disease models. By increasing PCK1, the drug diverts metabolic pathways away from fat synthesis toward glucose production. Researchers confirmed this glucose was not accumulating dangerously in the bloodstream, ruling out a diabetic risk.
This finding represents the first time researchers identified PCK1's role in how telmisartan combats early-stage disease. Previous work had focused on the drug's anti-inflammatory and anti-fibrotic effects, which matter more in advanced stages when scarring has already begun. In early disease, when only lipid accumulation exists, a different mechanism applies.
The combination therapy concept exploits synergistic effects. By acting through separate biological pathways, each drug enhances the other's benefit while lower doses reduce individual drug toxicity. This approach may prove superior to using single medications alone.
Still, the research remains preliminary. Findings in animal studies do not automatically translate to humans. Alegret emphasized that clinical trials in patients will be necessary before any treatment recommendation can be made. The team is now investigating whether the combination works in more advanced disease stages involving liver scarring, and whether benefits extend to atherosclerosis prevention in models that combine liver and heart disease.
Author Jessica Williams: "Early-stage breakthroughs using old drugs beat experimental failures every time, and this one targets both the liver and the heart in the same shot."
Comments